Through our analysis, we noticed that the Market Access area is usually related to drugs and private health system. We barely observed association with devices, unless it is implicit under general health services/assistance.
We observed a lack of training for the Market access area professionals, which results in poor executions of their duties.
There is a broad and different opinions and perspectives to define Market Access
The Market access area in Brazil still a recent area, with a few uncertainties, including for those who work in the area.
In Brazil there is no clear definition of area objectives and capabilities, noticing that each company has a different structure for the Market Access Area. Some companies' Market access only consider the activity of build a relation with the payers, other see the whole process including regulatory affairs, pricing & reimbursement, HTA, advocacy (Figure 3) .
The knowledge of a professional market access is diverse. Due to this, the Market Access area should be multidisciplinary and we can observe by the answers an important difficulty to find professionals by the pharmaceutical companies human resources area. In figure 3 , we can identify the key elements of market access are/professional: 
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ABSTRACT OBJECTIVES: Innovation in healthcare has become increasingly expensive making it difficult for pharmaceutical companies (PHARMAS) to have their products reimbursed. The Brazilian context is even more complex due to the current economic crisis, complex incorporation pathway in the private market and accelerated growth of the generics market. Thus, most PHARMAS are strategically investing in the Public and Private Healthcare Market Access (MA) area. We aimed to analyze whether pharma professionals (PP) in Market Access understand the importance, challenges and requirements of this new area.
METHODS:
We conducted a survey with PP (sales, marketing, medical affairs, market access) from various PHARMAS in 2014, consisting of a questionnaire with open questions about the definition of market access and challenges or doubts about the topic.
RESULTS:
A total of 136 professionals from 6 different multinational PHARMAS answered the survey. We observed a great dissonance about their definition of market access. Most responders believed MA should focus on patients' access, not just to drugs, but also to procedures and hospitalizations. About 75% (n = 102) stated concerns and obstacles to MA success. The majority focused on asking how to obtain specific product incorporation, and which were the pathways and criteria for technology incorporation in both public and private Brazilian healthcare systems. Most reported difficulties are the lack of integration between MA and other areas in the company, dissonance of objectives and points-of-view among healthcare players and the lack of qualified professionals in Brazil.
CONCLUSION:
There was a great disparity in the definitions of what is market access, most likely due to the relatively recent interest in the area in Brazil. Also, many PP still do not have enough training to build a successful MA strategy, besides lacking the necessary integration with other areas to achieve their objectives.
In the past, the evidence of safety and some effectiveness of a product was enough for a drug reach the market successfully. However, in the last decades, a more challenging scenario for new drugs is rapidly in development, mainly held by the exponential rise of health technology costs and restricted budget, international economic crisis, entering of competitors in the market, like biosimilar and generic drugs, increasing use of evidence-based medicine and health technology assessment (HTA), lack of innovation and increasing costs in R&D by pharmaceutical companies and establishment of HTA agencies.
This scenario changed the strategy and focus of the pharmaceutical companies and professionals, previous focused just in market authorization and regulatory approval, for the need to demonstrate the clinical-economic value of the product.
Worldwide, the traditional model for selling medicines with large sales teams is gradually been changing for account managers and specialists like market access professionals, changing the focus from prescribers to payers/government
In Brazil, we are also living a silence rupture in the form and model of medicines commercialization, through an increasingly sharper adoption of the institutional paying
The necessity of financing high cost drugs and procedures in the Brazilian Healthcare scenario led the companies initially to create the so called "funding area" in order to provide access of their products not out-of-pocket to patients.
With the growing scenario complexity with the need of "financiers" of these technologies (insurance plans, government) and implementation of Health Technologies Assessment (HTA) process with the creation of HTA agencies and the list of procedures for the Private Healthcare System, in the last years, pharmaceutical companies are rethinking their business model and structuring the Market Access area, focusing in the Public and Private Healthcare System and also Patients groups and non-governmental organizations (Figure 1) .
When asked about one difficulty or specific case in Market access, 75% of the participants (102/136) answered this question, of those 12% of the respondents would like to understand better the process for obtaining reimbursement for a product, and nearly 6% would like to understand the regulatory issues from the National Regulatory Agency for Private Health Insurance and Plans (ANS) or how to perform an effective job in Market access ( Table 1) .
We observe a major focus on the Private Healthcare System by the professionals in comparison to the Public Healthcare System ( Table 2 ).
• • Due to the recent need and creating the access area by pharmaceutical companies, some internal conflicts in the same company are observed ( Table 2) While analyzing the answers we could find that the professional have internal concerns within the area considering the lack of integration with other areas and the definition of Market access role and goals the most important ones ( Table 2 ).
• • According to the Tag Cloud analysis of the answers of both questions we noticed that Drug, Company and Access, had a higher frequency, followed by Payers, Health, Coverage, Decisions and Difficulty as seen on the figure below:
We conducted a primary research through questionnaires among Brazilian pharmaceutical professionals from different areas (sales, marketing, medical affairs, market access and health economics) in seven different pharma industries in the city of São Paulo -Brazil, between the months of July and December 2014.
The survey consisted in two open-ended questions:
The answers content were tabulated, grouped and analyzed by patterns of answers by two researchers. The results were presented descriptively and quantitatively.
We also used a technique called "Tag Cloud", which consists mainly in a visual representation, perceiving the most prominent terms. • Evidence generaƟon, including value story and value dossier development
• Health technology assessment analysis
• Medicine Based Evidence
• Analyzing clinical data prospecƟvely and retrospecƟvely to generate "real world evidence" and value for money
• Communica�ng outcomes and pricing decisions with the payers
• Forming or aligning with paƟent groups for effecƟve reimbursement strategies
• Developing strategy for government payers, health plans, physician groups, hospitals, etc.
• Establish and maintain relaƟonships with key payers
• Developing pricing and reimbursement strategy (including pricing bands, launch order, etc.) for launch products, and maintaining over Ɵme
• Determining contracƟng/net price strategy (including risk sharing arrangements, discounƟng, etc.)
• Developing and execuƟng reimbursement support and paƟent assistance services to ensure paƟent access to products
The main objective of this research is to analyze the perception of pharma professionals in the Brazilian Market Access area importance and functions, as well to understand challenges and perspectives for this new area.
RESULTS
When we asked the responders "How would you define Market access?", we found no homogeneity for the answers.
According to Graphic 1, approximately 15% defined Market Access as Access to drugs, medical care and hospitalizations, followed by Health assistance (12%) and Access only to drugs (8.2%) In order to improve these professionals knowledges and skills, some actions need to me taken in all spheres, including: 
